Exploring Predictors of Symptoms Relapse After Discontinuation of Successful 3-Month of Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Trial.
Phase of Trial: Phase IV
Latest Information Update: 21 Apr 2011
At a glance
- Drugs Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 21 Apr 2011 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 21 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2009 Planned end date changed from Dec 2008 to Oct 2009 as reported by ClinicalTrials.gov.